Wednesday, June 10, 2026
🇺🇸 FDA

biotech · Fabry Disease (X-linked lysosomal storage disease). · Kidney Transplant Rejection · SGMO

SANGAMO THERAPEUTICS

SANGAMO THERAPEUTICS, INC

SANGAMO THERAPEUTICS trial registry — 29 ClinicalTrials.gov studies with program phase, status, and indication context.

Website Investor relations
7000 Marina Blvd, Brisbane, California 94005, US HQ
1995 Founded
266 Employees
Public company Type
SGMO · NYSE Ticker
Company details
Status
Public
HQ
7000 Marina Blvd, Brisbane, California 94005, US
Founded
1995
Employees
266
Programs
25
Drugs
14
Patents
192
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Clinical Trials

SANGAMO THERAPEUTICS clinical trials

Registry index of 29 ClinicalTrials.gov studies linked to SANGAMO THERAPEUTICS programs — each row shows trial ID, program name, phase, status, and indication.

SANGAMO THERAPEUTICS trial registry — 29 ClinicalTrials.gov studies with program phase, status, and indication context.

Recent trial activity

8 updates

Latest clinical program signals indexed for SANGAMO THERAPEUTICS.

  1. ST-920 — Phase 2

    Clinical update

  2. ST-920 — Phase 2

    Clinical update

  3. ZFN modified T cells — Phase 1

    Clinical update

  4. SB-728mR-HSPC Infusion 3 days following busulfan conditioning — Phase 1

    Clinical update

  5. SB-728-T — Phase 2

    Clinical update

  6. ST-400 Investigational product — Phase 2

    Clinical update

  7. CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) — Phase 2

    Clinical update

  8. CERE-120: Adeno-Associated Virus Delivery of Neurturin — Phase 2

    Clinical update

Trial registry

29 studies

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.